We describe a comparative evaluation of commercial fluorescent treponemal antibody-absorbed test kits, using 150 selected patient sera. The ability of the test kits to detect reactive sera varied from 82.5 to 95%; that for nonreactive sera varied from 80.9 to 96.4%. Reproducibility of reactive and nonreactive results, measured by between-assay and within-assay studies, averaged 42%. The results showed substantial variation in performance characteristics among the kits, with important clinical implications for the diagnosis of syphilis. We recommend the development of an immunological standard for use in the manufacture of fluorescent treponemal antibody-absorbed test kits, with the goal of obtaining uniform performance characteristics among commercial test kits.
The fluorescent treponemal antibody-absorbed (FTA-ABS) test is currently the most widely used test for serological confirmation of syphilis. Since the introduction of the FTA-ABS test in 1964 (18) , a number of studies have demonstrated the value of the method for detection of specific antibody produced in response to infection by Treponema pallidum (1, 5, 6, 9, 13, 21, 25) . Currently, a number of manufacturers produce FTA-ABS test kits consisting of frozen multiwell slides containing fixed T. pallidum organisms, sorbent, buffer solutions for slide rinses, fluorescein isothiocyanate (FITC)-conjugated anti-human antibody produced in goats or rabbits, and reactive and nonspecific controls. The FITC conjugate included in commercial test kits often is prediluted to an expected optimal working dilution, in contrast to the standard test (33) . Manufacturers produce kit components matched by lot to achieve a projected level of reactivity and recommend that pretitrated conjugate be used without modification. Use of this type of commercial kit now dominates FTA-ABS testing in the United States. Some manufacturers voluntarily submit FTA-ABS reagents to the Centers for Disease Control (CDC) premarket evaluation program, which periodically reports lots of reagent that are approved after testing by CDC standards.
To our knowledge, no comparative laboratory evaluation of the many different test kits currently in use has been reported. We report the evaluation of the performance characteristics of four of the most widely used commercial FTA-ABS test kits. MATERIALS Reproducibility studies. Five of the nonreactive samples and two samples from the borderline and each group of reactive specimens were divided into two aliquots and were tested blindly by using different identification codes to obtain within-assay reproducibility data (see Table 3 ). The 7 control specimens and 20 samples consisting of 8 nonreactive, 2 borderline, 3 1 + reactive, 3 2 + reactive, 2 3 + reactive, and 2 4+ reactive specimens were tested in duplicate trials to obtain between-assay reproducibility data (see Tables 2 and 4) .
Test method. All testing was performed during a 1-week period by one highly experienced technologist. Due to the close proximity of the test areas on the multiwell substrate slides, the slide washing procedure was very carefully performed to minimize the possibility of any cross contamination from one well to the next. All results were read by using a Zeiss model 15 fluorescence microscope with incident illumination with a BP 450-490 exciter filter, an FT 510 dichromatic beam splitter, an LP 520 barrier filter, and a Neofluar x40 objective. Reading consisted of an initial transmitted-light examination of each well at x400 magnification to verify the proper condition of the well and rule out any interfering phenomena such as insufficient treponemes, debris, autofluorescence, etc., followed by a fluorescent light examination to determine reactivity and intensity of fluorescence. The following guideline was employed in grading the intensity of the fluorescence: very strongly fluorescent, 4+ reactive; strongly fluorescent, 3+ reactive; moderately fluorescent, 2+ reactive; weakly fluorescent or equivalent to minimally 1+ reactive control, 1+ reactive; visible fluorescence but definitely less than the 1 + reactive control, borderline; and vaguely visible fluorescence or nonfluorescent, nonreactive. RESULTS The percent agreement of the results of the three test kits evaluated is shown in Table 1 . Percent agreement for nonreactive specimens was 87% for Virgo, 86% for Beckman, and 42% for CSI. The relatively low correlation of the CSI kit with the control kit for negative (nonreactive and borderline) specimens is the result of 58 nonreactive specimens which gave borderline or weakly reactive (1+) results with the CSI kit (see Fig. la ). The percent agreement for combined nonreactive and borderline specimens was 98.2% for Virgo, 96.4% for Beckman, and 80.9% for CSI.
The percent agreement of reactive specimens by grade of fluorescence is shown in Table 1 . The percent of reactive specimens for which a grade of fluorescence identical to the control kit was obtained was 50% for Beckman, 45% for CSI, and 35% for Virgo. The percent agreement between control and test kit for reactive specimens plus or minus one (Fig. la) . The Virgo kit correlated well with the control for nonreactive specimens but correlated poorly with regard to reactive specimens, obtaining negative results for 7 (17.5%) of the 40 reactive specimens (Fig. lc) . ancies between the expected control value and the observed control value were obtained with all kits except the control kit. Expected control values were obtained in at least one of the two trials for all kits except the 1 + control of the Beckman kit (borderline results in both trials) and of the Virgo kit (2+ results in both trials). Borderline results were obtained for the nonspecific sorbent and phosphate-buffered saline controls in one trial, each with the Virgo kit. Tables 3 and 4 show the results of studies of the reproducibility of the test kits by comparison of between-and withinassay results. Reproducibility of the control kit, measured as the percentage of specimens producing the same result in daily repeated testing of clinical specimens, was 92%. The expected result was reproduced less than half of the time by all other kits (average 42%). The CSI kit reproduced the control result in the highest proportion for both the betweenassay (45%) and within-assay (47%) results. In addition, the CSI kit obtained the highest percent for reproduction of its own test result, between assay (60%) and within assay (87%) ( Table 5) . DISCUSSION The results of our study show that commercially prepared FTA-ABS test kits vary substantially in their ability to detect reactive and nonreactive specimens, and they fail to reproduce test results consistently. The source of variation probably resides in one or more of the kit components, such as sorbent, FITC conjugate, or T. pallidum organisms fixed on slides.
The FTA test, originally introduced without the use of sorbent (7) this, the FTA-ABS test, using the Reiter treponeme suspension as sorbent, has gained wide acceptance and has been examined in a number of clinical investigations (3, 5, 6, 9, 13, 21, 25) .
Sorbent should be considered a potential source of variation for the following reasons. Strain variation frequently occurs during serial in vitro culture passages. Failure to adhere to proper use offrozen stocks for batch production of Treponema reiteri by one manufacturer would result in a sorbent with properties that diverge from that of other manufacturers. 1ssentially, sorbent is spent treponemal growth medium. Potential variation resides in the protein digests present in the medium which vary from lot to lot and from source to source and are produced by processes that are difficult to control and standardize. Antibody employed in the synthesis of the FITC conjugate has been shown to cause variable FTA test results (14, 20) , and the titer of the B  B  B   --11  1  1  2  3  3  3  2  12  1  2  2  2  2  1  1  13  1  B  B  B  1   -B  14  2  2  2  1  3  1  3  15  2  3  2  2  3  2  2  16  2  2  3  2  3  1  3  17  3  2  3  3  4  3  3  18  3  2  3  2  3  2  2  19  4  4  4 
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conjugate has been demonstrated to affect sensitivity (6, 14) . The immunological properties of the current polyclonal type of FITC antibody, especially avidity and specificity, vary among manufacturers (14, 20) . In recognition of this, the use of a class-specific anti-immunoglobulin G conjugate has been recornmended (19) , and monoclonal conjugates are being developed and tested. It has also long been known that the concentration and quality of the FITC dye used in conjugate synthesis is a significant factor in the production of nonspecific staining (4, 16) . Although potentially less likely to be a source of variation, the techniques of growth, harvest, and preparation of T. pallidum fixed to multiwell slides must be considered as well. Strain variation in the in vivo passage of T. pallidum is an additional possibility.
Technical factors can be a source of discrepant results for the FTA-ABS test. These include serum runover, a pitfall for multiwell slide-type methods (17) ; the "bad well" phenomenon, ascribed primarily to a lack of a sufficient number of T. pallidum organisms in random wells; variable microscope performance caused by deteriorating mercury vapor lamptype light sources (33); and technologist subjectivity (17) . The results of our study are unlikely to be affected by the aforementioned technical factors owing to the experimental design and practical care exercised in the conduct of the tests.
The potential clinical significance of the study is worthy of note. Typically, the rate for false-positive FTA-ABS results has been reported as ca. 1% in normal individuals (9, 13, 21, 25) . However, rates as high as 14 to 17% have been observed in hospitalized patients (1, 5, 9, 25), and it has been shown that the presence of abnormal globulins in the blood of diseased and elderly patients also correlates with increased incidence of FTA-ABS reactivity (30) . Also, certain diseases and clinical entities other than syphilis can apparently result in a weakly false-positive FTA-ABS test. These include lupus erythematosus (22-24, 27, 30, 32) , rheumatoid arthritis (1, 13, 25, 32), herpes infection (3, 6, 35) , pregnancy (2, 10, 26), heroin addiction (11), cirrhosis (25) , uveitis (13, 29) , diabetes (1, 32), tuberculosis (1, 13, 32), asthma (1, 32), Hashimoto's thyroditis (1), cancer (12, 25) , hypergammaglobulinemia (1), and chronic urticaria (32 21, 25) . Our data showed that the Virgo kit did not detect 17.5% of reactive specimens. At the very least, delay of the correct diagnosis could occur in an actual clinical situation. Overall, the reproducibility of the test kits examined was marginal. Only the CSI kit exhibited a reasonably acceptable rate for reproducing a test result identical to the control kit and for reproducing its own result. Although results reported as reactive, borderline, or nonreactive may not change on repeat testing, the data are not likely to evoke confidence for the potential user. It is apparent that despite the presumed adherence of manufacturers to good practices and recognized controls, variation among FTA-ABS test kits occurs. We recommend the development of a more extensive immunological standard, perhaps a large panel of sera such as that used in this study, and the application of such a panel to the manufacture of FTA-ABS kits in an effort to obtain uniform performance among kits of different manufacturers. We advise the user of commercial FTA-ABS test kits to pay close attention to the CDC premarket evaluation reports regarding the suitability of individual lots of test kits and to be aware of the potential of discrepant test results for individual patients when the laboratory switches from one kit to another.
